Search Results - "Mathijssen, H"

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity by Filipski, K K, Mathijssen, R H, Mikkelsen, T S, Schinkel, A H, Sparreboom, A

“…Cisplatin is one of the most widely used anticancer agents for the treatment of solid tumors. The clinical use of cisplatin is associated with dose‐limiting…”
Get full text

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics by de Man, Femke M., Goey, Andrew K. L., van Schaik, Ron H. N., Mathijssen, Ron H. J., Bins, Sander

“…Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal,…”
Get full text

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy by Beumer, Jan H., Chu, Edward, Allegra, Carmen, Tanigawara, Yusuke, Milano, Gerard, Diasio, Robert, Kim, Tae Won, Mathijssen, Ron H., Zhang, Li, Arnold, Dirk, Muneoka, Katsuki, Boku, Narikazu, Joerger, Markus

“…5‐Fluorouracil (5‐FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International…”
Get full text

Determining the optimal dose in the development of anticancer agents by Mathijssen, Ron H. J., Sparreboom, Alex, Verweij, Jaap

“…Key Points The approved dose of anticancer drugs is often derived from empirical, small-scale studies rather than rationally conducted trials incorporating…”
Get full text

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective by van Leeuwen, Roelof W F, PharmD, van Gelder, Teun, Prof, Mathijssen, Ron H J, Prof, Jansman, Frank G A, Dr

“…Summary In the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and haemato-oncology. Because this new class of drugs is…”
Get full text

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial by Oza, Amit M, Prof, Cibula, David, Prof, Benzaquen, Ana Oaknin, MD, Poole, Christopher, Prof, Mathijssen, Ron H J, Prof, Sonke, Gabe S, MD, Colombo, Nicoletta, MD, Špaček, Jiří, MD, Vuylsteke, Peter, MD, Hirte, Holger, MD, Mahner, Sven, MD, Plante, Marie, MD, Schmalfeldt, Barbara, Prof, Mackay, Helen, MD, Rowbottom, Jacqui, PhD, Lowe, Elizabeth S, MD, Dougherty, Brian, PhD, Barrett, J Carl, PhD, Friedlander, Michael, Prof

“…Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade…”
Get full text

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine by Groenland, Stefanie L., Mathijssen, Ron H. J., Beijnen, Jos H., Huitema, Alwin D. R., Steeghs, Neeltje

“…Purpose While in the era of precision medicine, the right drug for each patient is selected based on molecular tumor characteristics, most novel oral targeted…”
Get full text

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients by Hurkmans, Daan P., Kuipers, Merian E., Smit, Jasper, van Marion, Ronald, Mathijssen, Ron H. J., Postmus, Piet E., Hiemstra, Pieter S., Aerts, Joachim G. J. V., von der Thüsen, Jan H., van der Burg, Sjoerd H.

“…Objectives A minority of NSCLC patients benefit from anti-PD1 immune checkpoint inhibitors. A rational combination of biomarkers is needed. The objective was…”
Get full text

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab by Heine, R J S D, Thielen, F W, Mathijssen, R H J, van Leeuwen, R W F, Franken, M G, Uyl-de Groot, C A

“…Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems…”
Get full text

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs by van Leeuwen, R W F, Brundel, D H S, Neef, C, van Gelder, T, Mathijssen, R H J, Burger, D M, Jansman, F G A

“…Background: Potential drug–drug interactions (PDDIs) in patients with cancer are common, but have not previously been quantified for oral anticancer treatment…”
Get full text

Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients by CIARIMBOLI, Giuliano, LANCASTER, Cynthia S, PUI, Ching-Hon, RELLING, Mary V, HERRMANN, Edwin, SPARREBOOM, Alex, SCHLATTER, Eberhard, FRANKE, Ryan M, SPROWL, Jason A, PAVENSTÄDT, Hermann, MASSMANN, Vivian, GUCKEL, Denise, MATHIJSSEN, Ron H. J, WENJIAN YANG

“…Knowledge of transporters responsible for the renal secretion of creatinine is key to a proper interpretation of serum creatinine and/or creatinine clearance…”
Get full text

A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients by Kuip, Evelien J. M., Zandvliet, Maarten L., Koolen, Stijn L. W., Mathijssen, Ron H. J., Rijt, Carin C. D.

“…Fentanyl is a strong opioid that is available for various administration routes, and which is widely used to treat cancer‐related pain. Many factors influence…”
Get full text

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells by van Jaarsveld, M T M, Helleman, J, Boersma, A W M, van Kuijk, P F, van IJcken, W F, Despierre, E, Vergote, I, Mathijssen, R H J, Berns, E M J J, Verweij, J, Pothof, J, Wiemer, E A C

“…Epithelial ovarian cancer is the most lethal gynecological malignancy in the Western world. A major impediment for the successful treatment is the development…”
Get full text

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer by van Soest, R.J, van Royen, M.E, de Morrée, E.S, Moll, J.M, Teubel, W, Wiemer, E.A.C, Mathijssen, R.H.J, de Wit, R, van Weerden, W.M

“…Abstract Introduction Treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years with the…”
Get full text

Effectiveness and safety of infliximab in cardiac Sarcoidosis by Bakker, A.L.M., Mathijssen, H., Azzahhafi, J., Swaans, M.J., Veltkamp, M., Keijsers, R.G.M., Akdim, F., Post, M.C., Grutters, J.C.

“…Immunosuppressive therapy in active cardiac sarcoidosis (CS) might prevent potential life-threatening complications. Infliximab (IFX) is a tumor necrosis…”
Get full text

Clinically relevant drug interactions with multikinase inhibitors: a review by Hussaarts, Koen G. A. M., Veerman, G. D. Marijn, Jansman, Frank G. A., van Gelder, Teun, Mathijssen, Ron H. J., van Leeuwen, Roelof W. F.

“…Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice…”
Get full text

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients by Karas, Spinel, Etheridge, Amy S., Nickerson, Deborah A., Cox, Nancy J., Mohlke, Karen L., Cecchin, Erika, Toffoli, Giuseppe, Mathijssen, Ron H. J., Forrest, Alan, Bies, Robert R., Innocenti, Federico

“…Background Irinotecan (CPT-11) is an anticancer agent widely used to treat adult solid tumours. Large interindividual variability in the clearance of…”
Get full text

Is uracil enough for effective pre-emptive DPD testing? by Heersche, Niels, Matic, Maja, Mathijssen, Ron H J, Coenen, Marieke J H, van Schaik, Ron H N

Get more information

Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors by van Elst, Jip M., IJzerman, Nikki S., Mathijssen, Ron H. J., Steeghs, Neeltje, Reyners, Anna K. L., de Haan, Jacco J.

“…Context Taste, smell, and mouthfeel disturbances are underrated and underreported, but important side effects of anti-cancer medication. These symptoms are…”
Get full text

Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children by Verscheijden, Laurens F M, Litjens, Carlijn H C, Koenderink, Jan B, Mathijssen, Ron H J, Verbeek, Marcel M, de Wildt, Saskia N, Russel, Frans G M

“…Morphine is a widely used opioid analgesic, which shows large differences in clinical response in children, even when aiming for equivalent plasma drug…”
Get full text